Qiagen N.V. (NYSE:QGEN) Q3 2023 Results Conference Call October 31, 2023 9:00 AM ET
Company Participants
John Gilardi - VP, Corporate Communications & IR
Thierry Bernard - CEO
Roland Sackers - CFO
Phoebe Loh - IR
Conference Call Participants
Catherine Schulte - R. Baird
Patrick Donnelly - Citi
Falko Friedrichs - Deutsche Bank
Jack Meehan - Nephron Research
Matt Sykes - Goldman Sachs
Casey Woodring - JPMorgan
Andrew Brackmann - William Blair
Operator
Ladies and gentlemen, thank you for standing by. I am Jess your Global Meet call operator. Welcome, and thank you for joining QIAGEN's Q3 2023 Earnings Conference Call Webcast. At this time, all participants are in a listen-only mode. Please be advised that this call is being recorded at QIAGEN’s request and will be made available on their internet website. A prepared remark will be followed by a question-and-answer session. [Operator Instructions]
At this time, I would like to introduce your host, Mr. John Gilardi, Vice President, Head of Corporate Communications and Investor Relations at QIAGEN. Please go ahead, sir.
John Gilardi
Thank you, Jess, and thank you all of you for joining us today for this call. We appreciate your interest in QIAGEN. Our speakers today are Thierry Bernard, our Chief Executive Officer; and Roland Sackers, our Chief Financial Officer. We also have Phoebe Loh from the IR team joining us as well. This call is being webcast live and will be archived on the Investors section of our website at www.qiagen.com. You can also find a copy of the quarterly results press release and presentation on our website. We'll begin with remarks from Thierry and Roland and then move into a Q&A session.
Before we start, let me briefly go over the safe harbor statement. The views expressed during this conference call and in response to your questions represent the perspectives of management as of today, October 31, 2023. We will be making statements and providing responses to your questions that convey our intentions, beliefs, expectations or predictions for the future.
These statements fall under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. They involve risks and uncertainties, and actual results may differ materially from those suggested by these statements. Factors that could influence results are mentioned in our filings with the SEC. These are also available on the SEC website and also on our own website.
QIAGEN disclaims any intention or obligation to update any forward-looking statements. Additionally, we will refer to certain financial measures not approved -- sorry, not prepared following generally accepted accounting principles or GAAP. All references to EPS refer to diluted EPS. You can find a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures in our press release and presentation.